Catherine Ramsey Schulte
Stock Analyst at Robert W. Baird
(4.70)
# 781
Out of 5,060 analysts
574
Total ratings
52.9%
Success rate
11.6%
Average return
Main Sectors:
Stocks Rated by Catherine Ramsey Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Reiterated: Buy | $265 → $348 | $393.44 | -11.55% | 42 | Aug 7, 2026 | |
| TWST Twist Bioscience | Reiterated: Buy | $65 → $115 | $132.75 | -13.37% | 47 | Aug 4, 2026 | |
| CSTL Castle Biosciences | Reiterated: Buy | $43 → $36 | $31.96 | +12.64% | 47 | Jul 31, 2026 | |
| TEM Tempus AI | Reiterated: Buy | $59 | $64.72 | -8.84% | 4 | Jul 31, 2026 | |
| TECH Bio-Techne | Reiterated: Hold | $49 → $73 | $72.57 | +0.59% | 43 | Jun 26, 2026 | |
| A Agilent Technologies | Reiterated: Buy | $155 → $156 | $172.97 | -9.81% | 44 | May 26, 2026 | |
| MTD Mettler-Toledo International | Reiterated: Hold | $1,445 → $1,194 | $1,622.29 | -26.40% | 28 | May 11, 2026 | |
| CAI Caris Life Sciences | Reiterated: Buy | $28 → $22 | $30.56 | -28.01% | 3 | May 8, 2026 | |
| GH Guardant Health | Reiterated: Buy | $120 → $129 | $158.60 | -18.66% | 2 | May 8, 2026 | |
| GRAL GRAIL | Reiterated: Buy | $82 → $70 | $117.81 | -40.58% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $363 → $387 | $436.95 | -11.43% | 44 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $129 → $117 | $152.64 | -23.35% | 43 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $53 → $43 | $46.13 | -6.79% | 14 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $653 → $639 | $690.00 | -7.39% | 56 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $249 → $245 | $229.04 | +6.97% | 30 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $3 | $6.79 | -55.82% | 23 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $11 | $16.42 | -33.01% | 28 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $109 → $137 | $262.54 | -47.82% | 54 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 8 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $102 | $92.36 | n/a | 1 | Mar 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $8 | $2.18 | n/a | 11 | Nov 2, 2018 |
Natera
Aug 7, 2026
Reiterated: Buy
Price Target: $265 → $348
Current: $393.44
Upside: -11.55%
Twist Bioscience
Aug 4, 2026
Reiterated: Buy
Price Target: $65 → $115
Current: $132.75
Upside: -13.37%
Castle Biosciences
Jul 31, 2026
Reiterated: Buy
Price Target: $43 → $36
Current: $31.96
Upside: +12.64%
Tempus AI
Jul 31, 2026
Reiterated: Buy
Price Target: $59
Current: $64.72
Upside: -8.84%
Bio-Techne
Jun 26, 2026
Reiterated: Hold
Price Target: $49 → $73
Current: $72.57
Upside: +0.59%
Agilent Technologies
May 26, 2026
Reiterated: Buy
Price Target: $155 → $156
Current: $172.97
Upside: -9.81%
Mettler-Toledo International
May 11, 2026
Reiterated: Hold
Price Target: $1,445 → $1,194
Current: $1,622.29
Upside: -26.40%
Caris Life Sciences
May 8, 2026
Reiterated: Buy
Price Target: $28 → $22
Current: $30.56
Upside: -28.01%
Guardant Health
May 8, 2026
Reiterated: Buy
Price Target: $120 → $129
Current: $158.60
Upside: -18.66%
GRAIL
May 6, 2026
Reiterated: Buy
Price Target: $82 → $70
Current: $117.81
Upside: -40.58%
May 6, 2026
Reiterated: Buy
Price Target: $363 → $387
Current: $436.95
Upside: -11.43%
May 4, 2026
Reiterated: Buy
Price Target: $129 → $117
Current: $152.64
Upside: -23.35%
Apr 29, 2026
Upgraded: Buy
Price Target: $53 → $43
Current: $46.13
Upside: -6.79%
Apr 24, 2026
Reiterated: Buy
Price Target: $653 → $639
Current: $690.00
Upside: -7.39%
Apr 22, 2026
Reiterated: Buy
Price Target: $249 → $245
Current: $229.04
Upside: +6.97%
Feb 26, 2026
Reiterated: Hold
Price Target: $2 → $3
Current: $6.79
Upside: -55.82%
Feb 12, 2026
Reiterated: Buy
Price Target: $17 → $11
Current: $16.42
Upside: -33.01%
Feb 6, 2026
Reiterated: Hold
Price Target: $109 → $137
Current: $262.54
Upside: -47.82%
Apr 18, 2022
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Mar 4, 2019
Reiterated: Buy
Price Target: $102
Current: $92.36
Upside: n/a
Nov 2, 2018
Reiterated: Buy
Price Target: $9 → $8
Current: $2.18
Upside: n/a